Clinical effect of Xuebijing combined with ulinastatin in the treatment of sepsis
Yang Xiaoting
Li Dan
Zhao Lixiao
Zhang Nan
Su Haiyan
Wang Yan
Xu Dandan
Zhao Lijun
Abstract：Objective To investigate the clinical effect of Xuebijing combined with ulinastatin in the treatment of sepsis.Methods Totally 78 patients with sepsis admitted to Zhangjiakou First Hospital,Hebei Province from March 2022 to January 2024 were selected.Patients were divided into observation group and control group by random number table method,with 39 cases in each group.The control group received ulinastatin for injection on the basis of comprehensive treatment.The observation group was treated with Xuebijing injection on the basis of the control group.Both groups were treated for 1 week and followed up until discharge.The clinical efficacy,traditional Chinese Medicine syndrome scale(TCM)score,acute physiology and chronic health evaluation Ⅱ(APACHE Ⅱ)score,sequential organ failure assessment(SOFA)score,thromboelastography(TEG)parameters,serological indicators and adverse reactions were compared between the two groups.Results After treatment,the total clinical effective rate of the observation group was higher than that of the control group[94.9％(37/39)vs 79.5％(31/39)](x2=4.129,P=0.042).After treatment,the TCM,APACHE Ⅱ and SOFA scores of the two groups were lower than those before treatment,and those of the observation group were lower than those of the control group(all P＜0.05).The TEG reaction time,coagulation time and maximum amplitude of thrombosis in the two groups were shorter/lower than those before treatment,and those in the observation group were shorter/lower than those in the control group(all P＜0.05).The levels of serum creatinine,cystatin C,procalcitonin,neutrophil gelatinase-associated lipocalin,kidney injury molecule 1,microRNA-223 and microRNA-155 in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(all P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P＞0.05).Conclusion Xuebijing combined with ulinastatin can improve the clinical symptoms and organ function of patients with sepsis,reduce the severity of the disease,stabilize TEG parameters,control the inflammatory response of the body,relieve kidney injury,with significant efficacy and good safety.
Keywords：SepsisXuebijingUlinastatin
Publication Date：2025-02-07
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：5( 231-235 )